Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-06-15ELVN144OrbiMed Genesis Master Fund, L.P. plan to sell securities of Enliven Therapeutics, Inc. under Form 144MEDIUM
OrbiMed Genesis Master Fund, L.P. filed Form 144 to notify SEC of plan to sell 9086 units of Enliven Therapeutics, Inc. securities around 2026-06-15, with aggregate market value of $384,882.96. The total outstanding units is 69822989.0. The amount planned to be sold represents 0.01% of total outstanding units; ...
Mid CapBiotechnology
2026-06-15ELVN144OrbiMed Private Investments VII, LP plan to sell securities of Enliven Therapeutics, Inc. under Form 144MEDIUM
OrbiMed Private Investments VII, LP filed Form 144 to notify SEC of plan to sell 272322 units of Enliven Therapeutics, Inc. securities around 2026-06-15, with aggregate market value of $11,535,559.92. The total outstanding units is 69822989.0. The amount planned to be sold represents 0.39% of total outstanding units; ...
Mid CapBiotechnology
2026-06-15ELVN144The Biotech Growth Trust PLC plan to sell securities of Enliven Therapeutics, Inc. under Form 144MEDIUM
The Biotech Growth Trust PLC filed Form 144 to notify SEC of plan to sell 10243 units of Enliven Therapeutics, Inc. securities around 2026-06-15, with aggregate market value of $433,893.48. The total outstanding units is 69822989.0. The amount planned to be sold represents 0.01% of total outstanding units; ...
Mid CapBiotechnology